Xencor, Inc. $XNCR Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. raised its stake in Xencor, Inc. (NASDAQ:XNCR) by 0.9% during the 4th quarter, HoldingsChannel reports. The firm owned 7,165,450 shares of the biopharmaceutical company’s stock after acquiring an additional 61,692 shares during the quarter. Vanguard Group Inc. owned 0.10% of Xencor worth $109,703,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Legal & General Group Plc lifted its position in Xencor by 603.7% during the 3rd quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock worth $14,932,000 after acquiring an additional 1,092,095 shares in the last quarter. Bank of America Corp DE lifted its position in Xencor by 94.5% during the 2nd quarter. Bank of America Corp DE now owns 938,993 shares of the biopharmaceutical company’s stock worth $7,380,000 after acquiring an additional 456,302 shares in the last quarter. Baker BROS. Advisors LP lifted its position in shares of Xencor by 64.4% during the third quarter. Baker BROS. Advisors LP now owns 1,102,106 shares of the biopharmaceutical company’s stock worth $12,928,000 after purchasing an additional 431,675 shares in the last quarter. UBS Group AG lifted its position in shares of Xencor by 51.4% during the third quarter. UBS Group AG now owns 1,175,267 shares of the biopharmaceutical company’s stock worth $13,786,000 after purchasing an additional 399,071 shares in the last quarter. Finally, Nantahala Capital Management LLC lifted its position in shares of Xencor by 79.6% during the second quarter. Nantahala Capital Management LLC now owns 820,103 shares of the biopharmaceutical company’s stock worth $6,446,000 after purchasing an additional 363,362 shares in the last quarter.

Xencor Trading Down 2.7%

NASDAQ XNCR opened at $12.44 on Wednesday. The company’s fifty day simple moving average is $12.27 and its 200-day simple moving average is $13.57. The stock has a market cap of $922.30 million, a P/E ratio of -5.43 and a beta of 0.93. Xencor, Inc. has a 52 week low of $6.92 and a 52 week high of $18.69.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). The company had revenue of $4.52 million during the quarter, compared to the consensus estimate of $27.86 million. Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The firm’s quarterly revenue was down 86.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.66) EPS. On average, research analysts expect that Xencor, Inc. will post -3.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on XNCR shares. Barclays boosted their target price on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. JPMorgan Chase & Co. boosted their target price on shares of Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. Zacks Research cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $24.50.

Insider Buying and Selling

In other Xencor news, CEO Bassil I. Dahiyat sold 6,606 shares of the company’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $11.02, for a total transaction of $72,798.12. Following the completion of the sale, the chief executive officer directly owned 546,316 shares of the company’s stock, valued at approximately $6,020,402.32. This represents a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Celia Eckert sold 3,244 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $36,495.00. Following the sale, the senior vice president directly owned 78,685 shares of the company’s stock, valued at $885,206.25. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 44,020 shares of company stock valued at $499,817 over the last 90 days. 5.23% of the stock is currently owned by company insiders.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.